<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="Sciences0024-32051879-0631Elsevier Inc. pmcid: 7443335S0024-3205(20)31088-2 doi: 10.1016/j.lfs.2020.118336118336 : Article COVID-19: Pathophysiology," exact="treatment" post="options, nanotechnology approaches, and research agenda to combating the"/>
 <result pre="caused by a novel corona virus and no approved specific" exact="treatment" post="is available yet. A vast number of promising antiviral"/>
 <result pre="aid in the development of COVID-19 drug delivery. The prospective" exact="treatment" post="options integrating the ever-expanding field of nanotechnology have been"/>
 <result pre="transmission, diagnosis, clinical presentations, prevention and pathophysiology of COVID-19 â€¢Current" exact="treatment" post="options for COVID-19 disease â€¢Nanotechnology approaches to aid in"/>
 <result pre="associated with post COVID-19 Keywords COVID-19 Nanotechnology Research agenda Therapeutics" exact="treatment" post="Post COVID-19 1 Introduction In December 2019, the World"/>
 <result pre="stages globally. The first stage, is when cases of an" exact="infection" post="are imported into a country from the other infectious"/>
 <result pre="stage of an outbreak and fourth stage is when an" exact="infection" post="becomes endemic with no clear endpoint. The world has"/>
 <result pre="19Â days, making it even more challenging to screen the" exact="infection" post="[3]. The care advised is to give fluid management,"/>
 <result pre="oxygen supportive as patients condition [4,5] and antibiotic in secondary" exact="infection" post="if any reported [6]. Based on evidence from laboratory,"/>
 <result pre="on evidence from laboratory, animal, and clinical studies, the following" exact="treatment" post="options were selected according to WHO: Remdesivir; Lopinavir/ritonavir; Lopinavir/ritonavir"/>
 <result pre="this pandemic- and that is through science. We need diagnostic" exact="detection" post="kit to detect and prevent the spread of the"/>
 <result pre="multiple countries. The WHO solidarity trial will provide this by" exact="testing" post="existing and new drug molecules to treat COVID-19 and"/>
 <result pre="death [14]. The most common laboratory method for the clinical" exact="diagnosis" post="of COVID-19 is nucleic acid detection by real time-"/>
 <result pre="method for the clinical diagnosis of COVID-19 is nucleic acid" exact="detection" post="by real time- PCR, which is further confirmed by"/>
 <result pre="1Â m distance, covering mouth-nose during coughing or sneezing. Practice" exact="physical distancing" post="devoid unnecessary travel and staying away from large groups"/>
 <result pre="staying away from large groups of peoples [27]. For early" exact="detection" post="of the virus, public awareness should be created regarding"/>
 <result pre="chronic cough or shortness of breath. Quarantine of suspected people," exact="isolation" post="of the infected people and their close contacts can"/>
 <result pre="SARS-CoV-2 infection, which may help to understand the routes of" exact="infection" post="and disease manifestations [32]. However, patients with SARS-CoV-2 infection"/>
 <result pre="of infection and disease manifestations [32]. However, patients with SARS-CoV-2" exact="infection" post="primarily exhibit lesions in the lungs, despite the ACE-2"/>
 <result pre="clinical studies, which raises the question of whether novel coronavirus" exact="infection" post="causes more deaths by multiple organ dysfunction syndrome (MODS)"/>
 <result pre="therapeutics approaches of virus-receptor binding affinity are under investigation. Systematic" exact="detection" post="of Î²-CoV receptors showed that human cells expressing ACE-2"/>
 <result pre="receptors showed that human cells expressing ACE-2 was enhanced the" exact="detection" post="of entry of SARS-CoV-2 but human Dipeptidyl peptidase-4 (DPP4)"/>
 <result pre="serum cytokine elevations, which may be a target of the" exact="treatment" post="of COVID-19 infected patients [35]. Excessive tissue damage is"/>
 <result pre="Avoidance is the principal method of deterrence. Searching of accurate" exact="treatment" post="for COVID-19 patients has been in progress and wide"/>
 <result pre="immune-therapies, monoclonal antibodies, and vaccines have rapidly emerged. These all" exact="treatment" post="is symptomatic but oxygen therapy using ventilator plays major"/>
 <result pre="but oxygen therapy using ventilator plays major role in the" exact="treatment" post="of COVID-19. All the recommended treatments for COVID-19 as"/>
 <result pre="Treatment options for covid-19 illustrating mechanical ventilation, monoclonal antibodies, drug" exact="treatment" post="by WHO, plasma therapy. 9 Mechanical ventilation When respiratory"/>
 <result pre="tissue hypo perfusion (strong recommendation) are emphasized [30]. 10 Drug" exact="treatment" post="option strategies to combat COVID-19 As previously discussed, no"/>
 <result pre="strategies to combat COVID-19 As previously discussed, no effective drug" exact="treatment" post="is available for fighting this COVID-19. But several drugs"/>
 <result pre="several anti-bacterial drugs have been available and using in the" exact="treatment" post="against COVID-19. Mostly combination of drugs serves as an"/>
 <result pre="against COVID-19. Mostly combination of drugs serves as an effective" exact="treatment" post="against COVID-19. Systemic corticosteroids (Hydrocortisone, methyl prednisolone, dexamethasone, and"/>
 <result pre="methyl prednisolone, dexamethasone, and prednisolone) are not recommended in the" exact="treatment" post="of viral pneumonia or ARDS due to the increased"/>
 <result pre="pneumonia or ARDS due to the increased mortality and secondary" exact="infection" post="rates in influenza, impaired clearance of SARS-CoV and MERS-CoV,"/>
 <result pre="Therefore, one should avoid in-appropriate administration of antibiotics, although some" exact="treatment" post="centre recommended it. Several approaches have been proposed such"/>
 <result pre="by the national medical products administration of China for the" exact="treatment" post="of COVID-19 [41]. Cai et al. performed an open-Label"/>
 <result pre="on COVID-19 patients. In these experiments, 35 patients were given" exact="treatment" post="of FPV and 45 patients were treated with lopinavir"/>
 <result pre="recover after drug withdrawal. Antiviral drugs should be stopped if" exact="nucleic acid test" post="results from sputum specimens remain negative for more than"/>
 <result pre="et al. conducted study on hydroxychloroquine and azithromycin as a" exact="treatment" post="toCOVID-19. It was found that patients treated with hydroxychloroquine"/>
 <result pre="that patients treated with hydroxychloroquine showed significant reduction in viral" exact="infection" post="as compared to the control. Hydroxychloroquine in combination with"/>
 <result pre="that no effect was found in mortality rate after HC" exact="treatment" post="and combination treatments but, significant reduction of mechanical ventilation"/>
 <result pre="of acute stroke and PCR (polymerase chain reaction) confirmed SARS-CoV-2" exact="infection" post="and elucidated the imaging findings, clinical characteristics, and the"/>
 <result pre="clinical course. Average time of onset of stroke after COVID-19" exact="diagnosis" post="was 12Â days. Elevated levels of D-dimer, C-reactive protein,"/>
 <result pre="Monoclonal antibody Various monoclonal antibody has been explored in the" exact="treatment" post="of COVID-19. Mainly, gimsilumab and leronlimab have been used"/>
 <result pre="COVID-19. Mainly, gimsilumab and leronlimab have been used in the" exact="treatment" post="of COVID-19. Gimsilumab targets a pro-inflammatory cytokine known as"/>
 <result pre="in combination with other neutralizing antibodies for the prevention and" exact="treatment" post="of COVID-19 infection. Leronlimab CCR5 is a protein on"/>
 <result pre="Leronlimab is a monoclonal antibody being studied as a potential" exact="treatment" post="for HIV. It binds to the CCR5 receptor, which"/>
 <result pre="its advancement Convalescent plasma (CP) is a promising plasma antibody" exact="treatment" post="that could help patients whose bodies cannot produce enough"/>
 <result pre="a national clinical trial to assess plasma therapy for the" exact="treatment" post="of COVID-19 patients. This trial will decide that these"/>
 <result pre="or not in the COVID-19 patients in future. If the" exact="treatment" post="will become effective, total 10,000Â units of convalescent plasma"/>
 <result pre="the patients in a scaled-up national programme that enabling the" exact="treatment" post="of 5000 patients per week [55]. Duan et al."/>
 <result pre="trials are urgently needed to conclude the optimal doses and" exact="treatment" post="time point for the CP therapy to tackle COVID-19"/>
 <result pre="at lung site. It was observed that treatments of lung" exact="infection" post="using large porous particle significantly reduced bacterial burden as"/>
 <result pre="nm can be highly effective to prevent and treat viral" exact="infection" post="at initial stage of respiratory infections [77]. Sarkar has"/>
 <result pre="activity [78]. Therefore, the anti-viral efficiencies of MNP for the" exact="treatment" post="of COVID-19can be explored with particular emphasis on formulation"/>
 <result pre="fullerene monoadducts and tested for antiviral activity in an experimental" exact="infection" post="assay using Ebola virus glycoprotein pseudotyped viral particles on"/>
 <result pre="have been utilized either as therapeutics or for in vitro" exact="diagnosis" post="of viral pathogens. Much progress has been made in"/>
 <result pre="of COVID-19 begins with understanding the virus origin, transmission and" exact="diagnosis" post="then therapeutic treatment strategies. The research regarding the natural"/>
 <result pre="with understanding the virus origin, transmission and diagnosis then therapeutic" exact="treatment" post="strategies. The research regarding the natural history of virus"/>
 <result pre="moment is the modification of clinical skill for the rapid" exact="diagnosis" post="of the infection and tracks the changes in virulence."/>
 <result pre="modification of clinical skill for the rapid diagnosis of the" exact="infection" post="and tracks the changes in virulence. Newly emerged virus"/>
 <result pre="immune responses work together in sequence to combat any viral" exact="infection" post="in healthy immune cells. In case of defective immune"/>
 <result pre="convalescent sera or other agents are also considered for the" exact="treatment" post="option. The research in the field of viral therapeutics"/>
 <result pre="2 List of different types of nanoparticles used for the" exact="treatment" post="of other viral infections. Table 2 S.noS.no Nanoparticle Virus"/>
 <result pre="might be a prospective silver species with antiviral properties for" exact="treatment" post="of viral diseases. [147] 3 Glutathione-capped Ag2S nanoclusters (NCs)"/>
 <result pre="nanotubes (CNTs) H1N1, norovirus DNA hybridization High sensitivity and selectivity" exact="detection" post="of viral DNA [155] 11 Monodispersed gold nanoparticles Herpes"/>
 <result pre="in conjunction to ARDS, RNAaemia, acute cardiac injury, and secondary" exact="infection" post="associated with other types of corona virus [142]. Sekowski"/>
 <result pre="The issue of negative detrimental impact of significant posttraumatic stress" exact="prevalence" post="of PTSD in individuals post COVID-19 remains a matter"/>
 <result pre="protective from secondary infection, according to WHO. Some countries suggested" exact="detection" post="of antibodies to COVIDâˆ’19, could serve as the basis"/>
 <result pre="Emergency response mechanisms, risk communication and public engagement case finding," exact="contact tracing" post="and management, surveillance, public health measures, laboratory testing are"/>
 <result pre="response mechanisms, risk communication and public engagement case finding, contact" exact="tracing" post="and management, surveillance, public health measures, laboratory testing are"/>
 <result pre="finding, contact tracing and management, surveillance, public health measures, laboratory" exact="testing" post="are the various priority areas of work in the"/>
 <result pre="development of animal models, in-vitro in-vivo studies to aid the" exact="screening" post="of antiviral drugs, prevent transmission of disease, and develop"/>
 <result pre="35MooreJ.B.JuneC.H.Cytokine release syndrome in severe COVID-19Science (80-)368202047347410.1126/science.abb8925 36YeQ.WangB.MaoJ.The pathogenesis and" exact="treatment" post="of the cytokine storm in COVID-19J. Inf. Secur.80202060761310.1016/j.jinf.2020.03.037 37WanS.YiQ.FanS.LvJ.ZhangX.GuoL.LangC.XiaoQ.XiaoK.YiZ.QiangM.XiangJ.ZhangB.ChenY.Characteristics"/>
 <result pre="(accessed June 15, 2020). 39RussellC.D.MillarJ.E.BaillieJ.K.Clinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injuryLancet395202047347510.1016/S0140-6736(20)30317-232043983 40WangY.ZhangD.DuG.DuR.ZhaoJ.Remdesivir in adults with severe"/>
 <result pre="by a SARS coronavirus-specific human monoclonal antibodyEmerg. Microbes Infect.9202038238510.1080/22221751.2020.172906932065055 42CaiQ.YangM.LiuD.ChenJ.ShuD.Experimental" exact="treatment" post="with Favipiravir for COVID-19: an open-label control studyEngineering202010.1016/j.eng.2020.03.007 43ChenC.HuangJ.ChengZ.WuJ.ChenS.ZhangY.ChenB.LuM.LuoY.ZhangJ.YinP.WangX.Favipiravir"/>
 <result pre="to combat COVID-19Life Sci.254202011776510.1016/j.lfs.2020.117765 49GautretP.LagierJ.C.ParolaP.HoangV.T.MeddedL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.DupontH.T.HonoreS.ColsonP.ChabriereE.La ScolaB.RolainJ.M.BrouquiP.RaoultD.Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: preliminary results of an open-label non-randomized clinical"/>
 <result pre="Acad. Sci. U. S. A.11720209490949610.1073/pnas.200416811732253318 57RajendranK.KrishnasamyN.RangarajanJ.RathinamJ.NatarajanM.RamachandranA.Convalescent plasma transfusion for the" exact="treatment" post="of COVID-19: systematic reviewJ. Med. Virol.20202596110.1002/jmv.25961jmv 58SivasankarapillaiV.S.PillaiA.M.RahdarA.SobhaA.P.DasS.S.MitropoulosA.C.MokarrarM.H.KyzasG.Z.On facing the"/>
 <result pre="deliveryCurr. Pharm. Des.2220162463246910.2174/138161282266616012814535626818876 69Garcia-ContrerasL.FiegelJ.TelkoM.J.ElbertK.HawiA.ThomasM.VerBerkmoesJ.GermishuizenW.A.FourieP.B.HickeyA.J.EdwardsD.A.Inhaled large porous particles of capreomycin for" exact="treatment" post="of tuberculosis in a Guinea pig modelAntimicrob. Agents Chemother.5120072830283610.1128/AAC.01164-0617517845"/>
 <result pre="bovine herpesvirus-1Int. J. Vet. Sci. Med.6201829630010.1016/j.ijvsm.2018.09.00230564612 77OSF preprints|formulations for COVID-19" exact="treatment" post="via silver nanoparticles inhalation delivery, (n.d). https://osf.io/adnyb (accessed June"/>
 <result pre="nanotubes as single-molecule biosensorsNano Lett.3200372773010.1021/nl034139u 89BurkeA.DingX.SinghR.KraftR.A.Levi-PolyachenkoN.RylanderM.N.SzotC.BuchananC.WhitneyJ.FisherJ.HatcherH.C.Dâ€™AgostinoR.KockN.D.AjayanP.M.CarrollD.L.AkmanS.TortiF.M.TortiS.V.Long-term survival following a single" exact="treatment" post="of kidney tumors with multiwalled carbon nanotubes and near-infrared"/>
</results>
